Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
Status:
Recruiting
Trial end date:
2024-03-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy, safety and tolerability of secukinumab in
Chinese patients with active nr-axSpA. Treatment difference of secukinumab 150mg vs. placebo
in Chinese nr-axSpA patients in terms of ASAS 40 response rate as well as safety profile will
be provided by the study.